Home Control (1747.HK) Announces Strategic Expansion into Healthcare Sector; Leveraging multi-disciplinary technologies which might include AIoT, Web3, expecting a potential increase in valuation
HONG KONG, Sept. 15, 2025 /PRNewswire/ -- On 12 September, Home Control (1747.HK) announced a strategic expansion into the healthcare sector with plans to establish a wholly owned subsidiary in Hong Kong. The new entity will focus on incubating and integrating smart healthcare hardware, with the aim of building a people-centric health services ecosystem. Market observers expect the initiative...
Phrontline Biopharma Announces First Patient Dosed in Phase 1 Clinical Trial of TJ101
SHANGHAI and SUZHOU, China, Sept. 15, 2025 /PRNewswire/ -- Phrontline Biopharma, a clinical-stage biotechnology company advancing a new generation of Antibody-Drug Conjugates (ADCs), today announced that the first patient has been successfully dosed in its Phase 1 clinical trial of TJ101, the company's lead asset targeting EGFR/B7-H3 with a proprietary linker-drug technology. "This is a critical milestone for Phrontline as we advance...
Lion TCR Achieves Triple FDA Milestones with IND Clearance for Chronic Hepatitis B Following Earlier Fast Track and Orphan Drug Designations
SINGAPORE and GUANGZHOU, China, Sept. 15, 2025 /PRNewswire/ -- Lion TCR, a clinical-stage biotechnology company pioneering T-cell receptor (TCR)-based therapies, today announced that it has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) to initiate phase1b/2 clinical trials for its proprietary TCR-T cell therapy, LioCyx-M004, in patients...
EverBridge Group and Cosmotec Forge Landmark Partnership
SHANGHAI, Sept. 15, 2025 /PRNewswire/ -- EverBridge Group announced an Exclusive Commercialization Partnership with Cosmotec Inc. (a Wholly Owned Subsidiary of M3, Inc.; TSE: 2413) for the Japanese market. Jay Wang (Left) and Suguru Ominato (Right) This strategic collaboration underscores EverBridge Group's leadership in proprietary R&D, stringent regulatory compliance, and value-driven ecosystem collaboration, marking a significant milestone...
Real-World Evidence of NEFECON® to Be Presented in Seven New Abstracts at the 18th International lgAN Symposium
7 new NEFECON® real-world evidence abstracts will be presented at the 18th International lgA Nephropathy Symposium (IIgANN 2025). The newly released results, based on clinical practices at several leading hospitals in China, offer a comprehensive overview of the efficacy and safety of NEFECON® in the treatment of IgA nephropathy (IgAN). NEFECON® clinical value was highlighted across three key dimensions, consistent with the new...
Senna Wellness Retreat introduces art showcase ‘Trăng Lên Đỉnh Núi’: A mid-autumn tribute to Kinh Bắc’s beauty and community spirit
BAC NINH, Vietnam, Sept. 13, 2025 /PRNewswire/ -- From 12 to 21 September 2025, Senna Wellness Retreat presents the art showcase 'Trăng Lên Đỉnh Núi' to embrace its Mid-Autumn campaign's message of festive togetherness. Set against the breathtaking backdrop of Northern Vietnam, the showcase invites guests, visitors, and collectors to immerse themselves in the healing landscapes of Kinh Bắc...
Prenetics Announces Second Quarter 2025 Financial Results with IM8 on Track to Achieve $100M Annual Recurring Revenue by Year’s End
1st Half revenue grew 452.1% to $32.3 million YoY IM8 achieved $5.9 million revenue in August 2025, representing a CAGR of over 3,100% Prenetics increases FY2025 revenue guidance range of $85 – $100 million Prenetics provides update on Bitcoin Treasury, adding a total of 228 Bitcoin, and accumulating 1 BTC daily Prenetics to achieve break-even in Q1 2026, and...
WFH mobilizes global community to achieve milestone revisions to WHO EML
MONTREAL, Sept. 12, 2025 /PRNewswire/ -- A concerted effort by the World Federation of Hemophilia (WFH) and its partners has led to the World Health Organization (WHO) updating its Essential Medicines List (EML) and the Essential Medicines List for Children (EMLc) to better align the EMLs to the international clinical guidelines for the...
LakeShore Biopharma Announces Receipt of Delisting Determination Letter from Nasdaq
BEIJING, Sept. 12, 2025 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that it received a staff determination letter (the "Letter") from the Nasdaq Stock Market LLC ("Nasdaq"),...
Pulnovo Medical Receives two IDE approvals for PADN system’s clinical trials with CMS coverage
SHANGHAI, Sept. 12, 2025 /PRNewswire/ -- Pulnovo Medical, a globally recognized leader in medical devices for pulmonary hypertension (PH) and heart failure (HF), is proud to announce that its PADN catheter and generator has received two Investigational Device Exemption (IDE) approvals—HDE study approved for patients with Group I PH patients, PMA study approved for patients with Group II PH...
